US Cigarette Sales Down, Marketing Budgets Up

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

WASHINGTON-Tobacco companies are not getting the same bang for their advertising dollars as they once did. Cigarette sales in the United States in 1999, the first year affected by the Master Settlement Agreement between the tobacco industry and 46 states, dropped despite an increase in spending for advertising and promotions.

WASHINGTON—Tobacco companies are not getting the same bang for their advertising dollars as they once did. Cigarette sales in the United States in 1999, the first year affected by the Master Settlement Agreement between the tobacco industry and 46 states, dropped despite an increase in spending for advertising and promotions.

In its annual report on cigarette sales and advertising, the Federal Trade Commission (FTC) said that domestic sales dropped to 411.3 billion cigarettes in 1999 from 458.5 billion in 1998, a decrease of 10.3%. The five largest cigarette companies hiked their spending for advertising and promotion in 1999 to $8.24 billion, an increase of 22.3% over 1998.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content